First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

BACKGROUND: The antitumour efficacy of tyrosine kinase inhibitors (TKIs) in lung cancer patients with compound epidermal growth factor receptor (EGFR) mutations has not been resolved. Our study summarizes a single institutional experience of first-generation TKI therapy for lung cancers with compoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiangyang, Zhang, Xuewen, Zhang, Zichen, Lin, Yongbin, Wen, Yingsheng, Chen, Yongqiang, Wang, Weidong, Zhang, Lanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064043/
https://www.ncbi.nlm.nih.gov/pubmed/30055651
http://dx.doi.org/10.1186/s40880-018-0321-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064043/
https://www.ncbi.nlm.nih.gov/pubmed/30055651
http://dx.doi.org/10.1186/s40880-018-0321-0

Ejemplares similares